In this study, we used targeted sequencing and CRISPR/Cas9 approaches to systematically characterize the biological effects of concurrent monoallelic or biallelic ATM and/or TP53 lesions in CLL cells in relation to patient clinical outcome. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.